HIV/AIDS: Public Health and Genomic Insights - June 12, 2015

Genomics|Features|HIV/AIDS

HIV/AIDS

HIV/AIDS: Public Health and Genomic Insights - June 12, 2015

CDC Info

• Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011.Buchacz K et al. J. Antimicrob. Chemother. 2015 May 15.
• Detection of acute HIV-1 infection by RT-LAMP.Rudolph DL et al. PLoS ONE 2015 (5) e0126609
• CDC information on HIV/AIDS
• CDC information on World AIDS Day
• CDC Vital Signs:HIV care saves lives. Viral suppression is key,November 2014

Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011.
Buchacz K et al. J. Antimicrob. Chemother. 2015 May 15.

A global health diagnostic for personalized medicine in resource-constrained world settings: A simple PCR-RFLP method for genotyping CYP2B6 g.15582C>T and science and policy relevance for optimal use of antiretroviral drug Efavirenz
Jonathan E et al, J Integrative Biology, June 2015

Detection of acute HIV-1 infection by RT-LAMP.
Rudolph DL et al. PLoS ONE 2015 (5) e0126609

Bottlenecks in HIV-1 transmission: insights from the study of founder viruses
Joseph SB et al, Nature Reviews Microbiology, June 8, 2015

The impact of host genetic variation on infection with HIV-1.
McLaren PJ et al. Nat. Immunol. 2015 May 19. (6) 577-583

Genome-wide association studies of HIV-1 host control in ethnically diverse Chinese populations.
Wei Z et al. Sci Rep 2015 10879

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- and sequence-level meta-analysis
Soo-Yon R et al. PLOS Medicine, April 2015

CDC information on HIV/AIDS

Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells.
Liao HK et al. Nat Commun 2015 6413

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
Zhu W et al. Retrovirology 2015 (1) 22

An integrated map of HIV genome-wide variation from a population perspective.
Li G et al. Retrovirology 2015 (1) 18

Novel genetic locus implicated for HIV-1 acquisition with putative regulatory links to HIV replication and infectivity: A genome-wide association study.
Johnson EO et al. PLoS ONE 2015 (3) e0118149

HIV latency and the noncoding RNA therapeutic landscape.
Saayman S et al. Adv. Exp. Med. Biol. 2015 169-89

Editing CCR5: A novel approach to HIV gene therapy.
Cornu TI et al. Adv. Exp. Med. Biol. 2015 117-30

Gene therapy strategies to block HIV-1 replication by RNA interference.
Herrera-Carrillo E et al. Adv. Exp. Med. Biol. 2015 71-95

Possible biomarkers for the early detection of HIV-associated heart diseases: A proteomics and bioinformatics prediction.
Rasheed S et al. Comput Struct Biotechnol J 2015 145-52

Targeting the HIV RNA genome: High-hanging fruit only needs a longer ladder.
Le Grice SF J et al. Curr. Top. Microbiol. Immunol. 2015 Mar 4.

Genome editing strategies: potential tools for eradicating HIV-1/AIDS.
Khalili K et al. J. Neurovirol. 2015 Feb 26.

The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.
Herrera-Carrillo E et al. Gene Ther. 2015 Feb 26.

The interplay between host genetic variation, viral replication, and microbial translocation in untreated HIV-infected individuals.
Perkins MR et al. J. Infect. Dis. 2015 Feb 20.

Data-intensive analysis of HIV mutations.
Ozahata M et al. BMC Bioinformatics 2015 Feb 5. (1) 35

HIV-1 adaptation to HLA: a window into virus-host immune interactions.
Carlson JM et al. Trends Microbiol. 2015 Jan 19.

Genomics of HIV infection.
Telenti A et al. Curr Opin HIV AIDS 2015 Mar (2) 77-8

Application of gene-editing technologies to HIV-1.
Drake MJ et al. Curr Opin HIV AIDS 2015 Mar (2) 123-7

Genome editing-based HIV therapies.
Gu WG et al. Trends Biotechnol. 2015 Mar (3) 172-179

HIV/AIDS: Recent Genomic Insights - December 4, 2014

CDC information on World AIDS Day

CDC Vital Signs: HIV care saves lives. Viral suppression is key, November 2014

Recent Advances

Review: influence of ART on HIV genetics. 
Simonetti FR, et al. Curr Opin HIV AIDS. 2014 Nov 11.

RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu W, et al.  PNAS, Jul 21, 2014.

Genome editing cuts out HIV
Grens K. The Scientist, Jul 21, 2014.

Gene researchers work to engineer HIV-resistant cells 
Hampton T. JAMA, Jul 9, 2014.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
Tebas P, et al. N Engl J Med. 2014 Mar 6;370(10):901-10.

Promising results from HIV gene editing therapy, PHG Foundation, Mar 10

Testing for risk and protective trends in genetic analyses of HIV acquisition.
Mccarthy JM, et al. Biostatistics. 2014 Sep 29

Biomarkers of HIV-associated Cancer.
Flepisi BT, et al. Biomark Cancer. 2014 Jul 3;6:11-20. doi

HIV/AIDS Genomics: Advances in Therapy and Tests - July 31, 2014

RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu W, et al.  PNAS, Jul 21, 2014.

Genome editing cuts out HIV
Grens K. The Scientist, Jul 21, 2014.

Gene researchers work to engineer HIV-resistant cells 
Hampton T. JAMA, Jul 9, 2014.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
Tebas P, et al. N Engl J Med. 2014 Mar 6;370(10):901-10.

Promising results from HIV gene editing therapy, PHG Foundation, Mar 10

Check out guidelines on genomic tests associated with HIV/AIDS treatment, from the CDC evidence-based table

HLA-B*5701/abacavir	DHHS Advisory Committee  [PDF 1.46 MB] (2013)  CPIC (2014) FDA-PGx Drug Information (2013)
CCR5-tropic HIV-1 /maraviroc	FDA-PGx Drug Information (2013) HHS Panel  [PDF 1.46 MB] (2013)

Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review
Cargnin S, et al. Pharmacogenomics. 2014;15(7):963-76.

Did you know? 1799 genes have been reported in relation to HIV risk & outcomes including 33 genomewide association studies. To find out more, visit the HuGE Navigator